Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Abstract

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

1 . An expression cassette, comprising a polynucleotide sequence encoding a polypeptide including an HIV Gag polypeptide, wherein the polynucleotide sequence encoding said Gag polypeptide comprises a sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; and SEQ ID NO:16.  
     
     
         2 - 10 . (canceled)  
     
     
         11 . A recombinant expression system for use in a selected host cell, comprising, an expression cassette of  claim 1 , and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected host cell.  
     
     
         12 . The recombinant expression system of  claim 11 , wherein said control elements are selected from the group consisting of a transcription promoter, a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.  
     
     
         13 . The recombinant expression system of  claim 11 , wherein said transcription promoter is selected from the group consisting of CMV, CMV+intron A, SV40, RSV, HIV-Ltr, MMLV-ltr, and metallothionein.  
     
     
         14 . A cell comprising an expression cassette of  claim 1 , and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected cell.  
     
     
         15 . The cell of  claim 14 , wherein the cell is a mammalian cell.  
     
     
         16 . The cell of  claim 15 , wherein the cell is selected from the group consisting of BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells.  
     
     
         17 . The cell of  claim 16 , wherein said cell is a CHO cell.  
     
     
         18 . The cell of  claim 14 , wherein the cell is an insect cell.  
     
     
         19 . The cell of  claim 18 , wherein the cell is either  Trichoplusia ni  (Tn5) or Sf9 insect cells.  
     
     
         20 . The cell of  claim 14 , wherein the cell is a bacterial cell.  
     
     
         21 . The cell of  claim 14 , wherein the cell is a yeast cell.  
     
     
         22 . The cell of  claim 14 , wherein the cell is a plant cell.  
     
     
         23 . The cell of  claim 14 , wherein the cell is an antigen presenting cell.  
     
     
         24 . The cell of  claim 23 , wherein the antigen presenting cell is a lymphoid cell selected from the group consisting of macrophages, monocytes, dendritic cells, B-cells, T-cells, stem cells, and progenitor cells thereof.  
     
     
         25 . The cell of  claim 14 , wherein the cell is a primary cell.  
     
     
         26 . The cell of  claim 14 , wherein the cell is an immortalized cell.  
     
     
         27 . The cell of  claim 14 , wherein the cell is a tumor-derived cell.  
     
     
         28 . (canceled)  
     
     
         29 . A gene delivery vector for use in a mammalian subject, comprising 
 a suitable gene delivery vector for use in said subject, wherein the vector comprises an expression cassette of  claim 1 , and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the subject.    
     
     
         30 - 57 . (canceled)